Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Exact Sciences Cor (EXAS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 2,646,658
  • Shares Outstanding, K 110,600
  • Annual Sales, $ 99,380 K
  • Annual Income, $ -167,210 K
  • 36-Month Beta 0.84
  • Price/Sales 26.98
  • Price/Cash Flow 0.00
  • Price/Book 7.84

Price Performance

See More
Period Period Low Period High Performance
1-Month
20.01 +19.59%
on 03/23/17
24.95 -4.09%
on 04/20/17
+3.79 (+18.82%)
since 03/21/17
3-Month
16.95 +41.18%
on 01/25/17
24.95 -4.09%
on 04/20/17
+5.84 (+32.28%)
since 01/20/17
52-Week
5.36 +346.46%
on 05/19/16
24.95 -4.09%
on 04/20/17
+16.11 (+206.01%)
since 04/21/16

Most Recent Stories

More News
Exact Sciences Up 38.0% Since SmarTrend Uptrend Call (EXAS)

SmarTrend identified an Uptrend for Exact Sciences (NASDAQ:EXAS) on January 9th, 2017 at $17.81. In approximately 3 months, Exact Sciences has returned 38.01% as of today's recent price of $24.58.

EXAS : 23.93 (-1.28%)
Watch for Exact Sciences to Potentially Pullback After Gaining 1.55% Yesterday

Exact Sciences (NASDAQ:EXAS) traded in a range yesterday that spanned from a low of $23.30 to a high of $24.19. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of...

EXAS : 23.93 (-1.28%)
29.4% Return Seen to Date on SmarTrend Exact Sciences Call (EXAS)

SmarTrend identified an Uptrend for Exact Sciences (NASDAQ:EXAS) on January 9th, 2017 at $17.81. In approximately 3 months, Exact Sciences has returned 29.42% as of today's recent price of $23.05.

EXAS : 23.93 (-1.28%)
Exact Sciences Up 27.4% Since SmarTrend Uptrend Call (EXAS)

SmarTrend identified an Uptrend for Exact Sciences (NASDAQ:EXAS) on January 9th, 2017 at $17.81. In approximately 3 months, Exact Sciences has returned 27.40% as of today's recent price of $22.69.

EXAS : 23.93 (-1.28%)
CMS includes Cologuard in updated Medicare Advantage Star Ratings

Exact Sciences Corp. (Nasdaq: EXAS) today announced that the Centers for Medicare and Medicaid Services (CMS) included Cologuard® in its updated Medicare Advantage Star Ratings program. Medicare Advantage...

EXAS : 23.93 (-1.28%)
Exact Sciences Grants Inducement Restricted Stock Unit Awards to Recently Hired Employees

Exact Sciences Corp. (NASDAQ: EXAS) today announced that, in support of the Company's continued growth plans, it granted restricted stock units covering a total of 85,421 shares of common stock to 77 recently...

EXAS : 23.93 (-1.28%)
Exact Sciences and Mayo Clinic study shows promise of new blood-based lung cancer test

A study from Exact Sciences Corp. (Nasdaq: EXAS) and Mayo Clinic released today by the American Association of Cancer Research (AACR) shows promise for the development of a blood-based lung cancer test....

EXAS : 23.93 (-1.28%)
Fight Colorectal Cancer and Exact Sciences Corp. (Nasdaq: EXAS) to Ring The Nasdaq Stock Market Closing Bell

What:

NDAQ : 69.91 (-0.30%)
EXAS : 23.93 (-1.28%)
Pfizer's Leukemia Candidate Gets Priority Review in U.S.

Pfizer Inc. (PFE) announced that its Biologics License Application (BLA) for leukemia candidate inotuzumab ozogamicin has been accepted for priority review by the FDA.

EXAS : 23.93 (-1.28%)
SNSS : 3.71 (-1.85%)
PFE : 33.64 (-0.30%)
GSK : 40.78 (+0.17%)
Exelixis (EXEL) Q4 Earnings: Is Positive Surprise in Store?

Exelixis, Inc. (EXEL) is scheduled to report fourth-quarter 2016 results on Feb 27, after the market close.

EXAS : 23.93 (-1.28%)
EXEL : 20.98 (-1.59%)
PCRX : 45.20 (-1.31%)
BMY : 53.48 (+0.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

EXACT Sciences Corporation uses applied genomics to develop effective, patient-friendly screening technologies for use in the detection of cancer. Certain of its technologies have been licensed to Laboratory Corporation of America Holdings for a stool-based DNA screening assay for colorectal cancer in...

See More

Support & Resistance

2nd Resistance Point 24.55
1st Resistance Point 24.24
Last Price 23.93
1st Support Level 23.61
2nd Support Level 23.29

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.